{'fraction_non_alphanumeric': 0.029250457038391225, 'fraction_numerical': 0.009140767824497258, 'mean_word_length': 5.682926829268292, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The research and development of a 5‐HT selective reuptake blocker. Preclinical aspects

ABSTRACT— The preclinical development of zimeldine according to the 5‐HT (serotonin) hypothesis is briefly reviewed. Zimeldine is a selective 5‐HT reuptake inhibitor based on the “chemical lead” of brompheniramine – an antihistamine with some 5‐HT reuptake inhibitory properties. By chemical manipulation of the position of the pyridine ring in brompheniramine and the stereochemistry of the side chain, a selective 5‐HT reuptake inhibitor has been developed.